ENXTPA:SANPharmaceuticals
Sanofi’s New China And EU Drug Approvals Versus Current Valuation
Sanofi (ENXTPA:SAN) has received approval in China for Myqorzo (aficamten) to treat obstructive hypertrophic cardiomyopathy.
Chinese regulators have also cleared Redemplo (plozasiran) for familial chylomicronaemia syndrome, a rare and severe lipid disorder.
The European Commission has approved Teizeild (teplizumab) as the first disease modifying therapy for type 1 diabetes in the EU.
Sanofi, trading at about €78.03 with a 1 year return of 17.7%, is expanding into both major emerging markets...